Replies to post #21801 on Biotech Values

[drbio45]

The cfo leaving shouldn't bother you because there weren't any revenues to screw around with.<

DNDN doesn’t have any material revenues either, and yet the announcement of the CFO’s departure there was a harbinger of poor performance for the stock.

I wouldn't sell a stock just because the cfo leaves. As with any piece of news it is one more thing to put into the equation of whether to buy or sell

The less the chance there is that the cfo conducted financial shananigans, the less importantance I would put on his leaving.

In this case the company has an early stage product with a lot of cash on the books. Not much for a cfo to do

[St_armands_man]

>The cfo leaving shouldn't bother you because there weren't any revenues to screw around with.<

DNDN doesn’t have any material revenues either, and yet the announcement of the CFO’s departure there was a harbinger of poor performance for the stock.

As previously noted, among all of the top executives in a biotech company, the CFO has the least to gain and the most to lose by sticking around when there are problems not fully known to investors.

As a CFO myself, I concur with your above statement (it usually applies to any publically traded company - not just biotech).